• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝癌患者中 GARP(+)CTLA-4(+)Foxp3(+) T 调节细胞和髓源抑制细胞的频率较高与 T 细胞功能受损有关。

Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality.

机构信息

Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.

出版信息

Cancer Res. 2013 Apr 15;73(8):2435-44. doi: 10.1158/0008-5472.CAN-12-3381. Epub 2013 Feb 19.

DOI:10.1158/0008-5472.CAN-12-3381
PMID:23423978
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3645275/
Abstract

The extent to which T-cell-mediated immune surveillance is impaired in human cancer remains a question of major importance, given its potential impact on the development of generalized treatments of advanced disease where the highest degree of heterogeneity exists. Here, we report the first global analysis of immune dysfunction in patients with advanced hepatocellular carcinoma (HCC). Using multi-parameter fluorescence-activated cell sorting analysis, we quantified the cumulative frequency of regulatory T cells (Treg), exhausted CD4(+) helper T cells, and myeloid-derived suppressor cells (MDSC) to gain concurrent views on the overall level of immune dysfunction in these inoperable patients. We documented augmented numbers of Tregs, MDSC, PD-1(+)-exhausted T cells, and increased levels of immunosuppressive cytokines in patients with HCC, compared with normal controls, revealing a network of potential mechanisms of immune dysregulation in patients with HCC. In dampening T-cell-mediated antitumor immunity, we hypothesized that these processes may facilitate HCC progression and thwart the efficacy of immunotherapeutic interventions. In testing this hypothesis, we showed that combined regimens to deplete Tregs, MDSC, and PD-1(+) T cells in patients with advanced HCC restored production of granzyme B by CD8(+) T cells, reaching levels observed in normal controls and also modestly increased the number of IFN-γ producing CD4(+) T cells. These clinical findings encourage efforts to restore T-cell function in patients with advanced stage disease by highlighting combined approaches to deplete endogenous suppressor cell populations that can also expand effector T-cell populations.

摘要

鉴于 T 细胞介导的免疫监视在人类癌症中的受损程度对广泛治疗高度异质性的晚期疾病的发展具有潜在影响,因此它仍是一个非常重要的问题。在这里,我们报告了对晚期肝细胞癌 (HCC) 患者免疫功能障碍的首次全球分析。我们使用多参数荧光激活细胞分选分析技术,对调节性 T 细胞 (Treg)、耗竭的 CD4(+)辅助 T 细胞和髓源性抑制细胞 (MDSC) 的累积频率进行定量,以同时了解这些不可手术患者的整体免疫功能障碍程度。与正常对照相比,我们记录到 HCC 患者的 Treg、MDSC、PD-1(+)耗竭 T 细胞数量增加,以及免疫抑制细胞因子水平升高,揭示了 HCC 患者免疫失调的潜在机制网络。在抑制 T 细胞介导的抗肿瘤免疫方面,我们假设这些过程可能促进 HCC 的进展,并破坏免疫治疗干预的疗效。在验证这一假设的过程中,我们表明,在晚期 HCC 患者中联合使用清除 Treg、MDSC 和 PD-1(+)T 细胞的方案可恢复 CD8(+)T 细胞产生颗粒酶 B,达到正常对照的水平,同时适度增加 IFN-γ 产生的 CD4(+)T 细胞数量。这些临床发现通过强调联合清除内源性抑制性细胞群的方法来恢复晚期疾病患者的 T 细胞功能,为患者提供了鼓励,这些方法还可以扩展效应 T 细胞群。

相似文献

1
Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality.肝癌患者中 GARP(+)CTLA-4(+)Foxp3(+) T 调节细胞和髓源抑制细胞的频率较高与 T 细胞功能受损有关。
Cancer Res. 2013 Apr 15;73(8):2435-44. doi: 10.1158/0008-5472.CAN-12-3381. Epub 2013 Feb 19.
2
A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells.肝癌患者中一群新的髓源性抑制细胞可诱导CD4(+)CD25(+)Foxp3(+) T细胞产生。
Gastroenterology. 2008 Jul;135(1):234-43. doi: 10.1053/j.gastro.2008.03.020. Epub 2008 Mar 21.
3
Myeloid-derived suppressor cells correlate with patient outcomes in hepatic arterial infusion chemotherapy for hepatocellular carcinoma.髓源性抑制细胞与肝细胞癌肝动脉灌注化疗患者的预后相关。
Cancer Immunol Immunother. 2016 Jun;65(6):715-25. doi: 10.1007/s00262-016-1837-2. Epub 2016 Apr 15.
4
Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma.调节性 T 细胞和检查点抑制在肝细胞癌中的作用。
Cancer Immunol Immunother. 2019 Dec;68(12):2055-2066. doi: 10.1007/s00262-019-02427-4. Epub 2019 Nov 13.
5
Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses.利用高维蛋白质组学和转录组学分析描绘肝细胞癌中的免疫抑制梯度。
Proc Natl Acad Sci U S A. 2017 Jul 18;114(29):E5900-E5909. doi: 10.1073/pnas.1706559114. Epub 2017 Jul 3.
6
Increased frequency of Foxp3+ regulatory T cells in mice with hepatocellular carcinoma.肝细胞癌小鼠中Foxp3 + 调节性T细胞频率增加。
Asian Pac J Cancer Prev. 2012;13(8):3815-9. doi: 10.7314/apjcp.2012.13.8.3815.
7
Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti-tumour immune responses.慢性乙型肝炎患者体内的调节性 T 细胞通过抑制抗肿瘤免疫反应来影响肝细胞癌的免疫发病机制。
J Viral Hepat. 2010 Mar;17 Suppl 1:34-43. doi: 10.1111/j.1365-2893.2010.01269.x.
8
Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC.低剂量环磷酰胺治疗可损害调节性 T 细胞,并使晚期 HCC 患者 AFP 特异性 CD4+ T 细胞反应显现。
J Immunother. 2010 Feb-Mar;33(2):211-8. doi: 10.1097/CJI.0b013e3181bb499f.
9
Increased liver-infiltrating CD8+FoxP3+ regulatory T cells are associated with tumor stage in hepatocellular carcinoma patients.在肝癌患者中,肝浸润的 CD8+FoxP3+调节性 T 细胞增多与肿瘤分期相关。
Hum Immunol. 2010 Dec;71(12):1180-6. doi: 10.1016/j.humimm.2010.09.011. Epub 2010 Sep 24.
10
T-regulatory cells and programmed death 1+ T cells contribute to effector T-cell dysfunction in patients with chronic obstructive pulmonary disease.调节性T细胞和程序性死亡1阳性T细胞导致慢性阻塞性肺疾病患者效应T细胞功能障碍。
Am J Respir Crit Care Med. 2014 Jul 1;190(1):40-50. doi: 10.1164/rccm.201312-2293OC.

引用本文的文献

1
GARP-expressing Tregs as a source of immunosuppressive TGF-β1 in human tumors.表达GARP的调节性T细胞作为人类肿瘤中免疫抑制性转化生长因子-β1的来源。
Cancer Immunol Immunother. 2025 Sep 13;74(10):308. doi: 10.1007/s00262-025-04157-2.
2
Number of Pretransplant Therapeutic Plasma Exchange Sessions Increase the Recurrence Risk of Hepatocellular Carcinoma in ABO-Incompatible Living Donor Liver Transplantation.移植前治疗性血浆置换次数增加ABO血型不相容活体肝移植中肝细胞癌的复发风险。
Transpl Int. 2025 Aug 13;38:14304. doi: 10.3389/ti.2025.14304. eCollection 2025.
3
Improving immunotherapy for the treatment of hepatocellular carcinoma: learning from patients and preclinical models.

本文引用的文献

1
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.抗 PD-1 抗体在癌症中的安全性、活性和免疫相关性。
N Engl J Med. 2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. Epub 2012 Jun 2.
2
Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue-imaging study.滤泡性淋巴瘤中细胞毒性 T 淋巴细胞的分布、功能和预后价值:一项 3D 组织成像研究。
Blood. 2011 Nov 17;118(20):5371-9. doi: 10.1182/blood-2011-04-345777. Epub 2011 Aug 19.
3
Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13.
改善肝细胞癌免疫治疗:从患者和临床前模型中学习。
Gut Liver. 2025 Apr 3;2(1). doi: 10.1038/s44355-025-00018-y.
4
Transcriptomic signatures in peripheral CD4T-lymphocytes may reflect melanoma staging and immunotherapy responsiveness prior to ICI initiation.外周血CD4 T淋巴细胞中的转录组特征可能反映黑色素瘤的分期以及在开始免疫检查点抑制剂治疗之前的免疫治疗反应性。
Front Immunol. 2025 Mar 28;16:1529707. doi: 10.3389/fimmu.2025.1529707. eCollection 2025.
5
The immunosuppressive role of MDSCs in HCC: mechanisms and therapeutic opportunities.髓源性抑制细胞在肝癌中的免疫抑制作用:机制与治疗机遇
Cell Commun Signal. 2025 Mar 27;23(1):155. doi: 10.1186/s12964-025-02170-7.
6
Delineation of monocytic and early-stage myeloid-derived suppressor cells in the peripheral blood of patients with hepatocarcinoma.肝癌患者外周血中单核细胞及早期髓系来源抑制细胞的鉴定
Int J Cancer. 2025 Jun 15;156(12):2416-2428. doi: 10.1002/ijc.35390. Epub 2025 Mar 7.
7
Transferrin Disassociates TCR from CD3 Signaling Apparatus to Promote Metastasis.转铁蛋白使TCR与CD3信号装置解离以促进转移。
Research (Wash D C). 2025 Jan 13;8:0578. doi: 10.34133/research.0578. eCollection 2025.
8
Liver resection and transplantation in the era of checkpoint inhibitors.免疫检查点抑制剂时代的肝切除与肝移植
JHEP Rep. 2024 Aug 6;6(11):101181. doi: 10.1016/j.jhepr.2024.101181. eCollection 2024 Nov.
9
[Research progress on ferroptosis regulation in tumor immunity of hepatocellular carcinoma].[肝细胞癌肿瘤免疫中铁死亡调节的研究进展]
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2024 Dec 25;53(6):715-725. doi: 10.3724/zdxbyxb-2024-0117.
10
First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors.在晚期实体瘤患者中,靶向GARP:TGF-β1复合物的抗体livmoniplimab作为单药疗法以及与抗PD-1抗体budigalimab联合使用的首次人体1期剂量递增结果。
Front Oncol. 2024 Oct 29;14:1376551. doi: 10.3389/fonc.2024.1376551. eCollection 2024.
在胰腺癌、食管癌和胃癌中,髓源性抑制细胞的升高是一个独立的预后因素,并且与 Th2 细胞因子白细胞介素-13 的显著升高相关。
Cancer Immunol Immunother. 2011 Oct;60(10):1419-30. doi: 10.1007/s00262-011-1028-0. Epub 2011 Jun 5.
4
Perspectives on Regulatory T Cell Therapies.调节性T细胞疗法的前景
Transfus Med Hemother. 2009;36(5):302-308. doi: 10.1159/000235929. Epub 2009 Sep 10.
5
Clinical significance of regulatory T cells and CD8+ effector populations in patients with human endometrial carcinoma.调节性 T 细胞和 CD8+效应细胞群体在人类子宫内膜癌患者中的临床意义。
Cancer. 2010 Dec 15;116(24):5777-88. doi: 10.1002/cncr.25371. Epub 2010 Aug 23.
6
Cancer statistics, 2010.癌症统计数据,2010 年。
CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300. doi: 10.3322/caac.20073. Epub 2010 Jul 7.
7
Regulatory T cells: how do they suppress immune responses?调节性T细胞:它们如何抑制免疫反应?
Int Immunol. 2009 Oct;21(10):1105-11. doi: 10.1093/intimm/dxp095. Epub 2009 Sep 7.
8
Expression of GARP selectively identifies activated human FOXP3+ regulatory T cells.GARP的表达可选择性地识别活化的人类FOXP3 +调节性T细胞。
Proc Natl Acad Sci U S A. 2009 Aug 11;106(32):13439-44. doi: 10.1073/pnas.0901965106. Epub 2009 Jul 28.
9
Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer.晚期非小细胞肺癌患者中表达 L-精氨酸酶和诱导型一氧化氮合酶的 CD11b+/CD14⁻/CD15+/CD33+髓源抑制性细胞和 CD8+T 淋巴细胞的群体改变。
J Cancer Res Clin Oncol. 2010 Jan;136(1):35-45. doi: 10.1007/s00432-009-0634-0.
10
GARP: a key receptor controlling FOXP3 in human regulatory T cells.GARP:调控人调节性 T 细胞中 FOXP3 的关键受体。
J Cell Mol Med. 2009 Sep;13(9B):3343-57. doi: 10.1111/j.1582-4934.2009.00782.x. Epub 2009 May 13.